ArticleJournal of clinical medicine2022

Phase 1 and 2 Randomized Clinical Studies Determine Lack of Efficacy for Anti-IL-17C Antibody MOR106 in Moderate-Severe Atopic Dermatitis.

Diamant Thaçi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.